BIOGEN INC. (BIIB)
Biological Products, (No Diagnostic Substances)
Latest Price
$202.95
TTM P/E
21.82
Normalized P/E
17.29
Div Yield
--
Book Value
126.71
P/B Ratio
1.60
Valuation metrics
adjust assumptions →EPS: $8.79
Book value / share: $124.37
Formula: √(22.5 × EPS × BVPS)
Graham Number
$156.83
23% downside
Norm. op. income: $4.6B (median of 3yr)
Tax rate: 16%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$237.25
+17% upside
Base FCF: $2.1B (median of recent 5yr)
Growth: -13%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$44.88
78% downside
EPS: $8.79
Target P/E: 17×
Formula: EPS × P/E
P/E Fair Value
$149.43
26% downside
Institutional Ownership
88.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15.97M | $2.93B | 10.85% | +1.16M | 2026-03-31 |
| PRIMECAP MANAGEMENT CO/CA/ | 14.76M | $2.71B | 10.03% | -390 | 2026-03-31 |
| FMR LLC | 12.81M | $2.35B | 8.70% | +3.38M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.54M | $1.75B | 6.48% | -- | 2026-03-31 |
| STATE STREET CORP | 7.17M | $1.31B | 4.87% | +8.9K | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.53M | $1.20B | 4.44% | -- | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.34M | $793.0M | 2.95% | +143.2K | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.96M | $542.0M | 2.01% | -589.6K | 2026-03-31 |
| MORGAN STANLEY | 2.17M | $397.0M | 1.47% | -154.1K | 2026-03-31 |
| AQR CAPITAL MANAGEMENT LLC | 1.92M | $346.0M | 1.31% | +394.9K | 2026-03-31 |